Simcere Pharmaceutical Group Ltd
HKEX:2096
Simcere Pharmaceutical Group Ltd
HKEX:2096
Price:
13.97
HKD
2.05%
Market Cap:
HK$36.3B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Simcere Pharmaceutical Group Ltd
HKEX:2096
|
CN |
|
Karat Packaging Inc
NASDAQ:KRT
|
US |
|
K
|
Koryo Credit Information Co Ltd
KOSDAQ:049720
|
KR |
|
Senetas Corp Ltd
ASX:SEN
|
AU |
|
C
|
Churchill Resources Inc
XTSX:CRI
|
CA |
|
Galva Technologies Tbk PT
IDX:GLVA
|
ID |
|
Kloeckner & Co SE
XETRA:KCO
|
DE |
|
FTI Foodtech International Inc
XTSX:FTI
|
CA |
|
C
|
China Steel Corp
TWSE:2002
|
TW |
|
63 Moons Technologies Ltd
NSE:63MOONS
|
IN |
|
AL Group Ltd
HKEX:8360
|
HK |
|
R
|
Radici Pietro Industries & Brands SpA
MIL:RAD
|
IT |
|
Toei Co Ltd
TSE:9605
|
JP |
Multiples-Based Value
The Multiples-Based Value of one
Simcere Pharmaceutical Group Ltd
stock under the Base Case scenario is
hidden
HKD.
Compared to the current market price of 13.97 HKD,
Simcere Pharmaceutical Group Ltd
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Simcere Pharmaceutical Group Ltd Multiples-Based Value
LOCKED
Multiples Across Competitors
Competitors Multiples
Simcere Pharmaceutical Group Ltd Competitors
Simcere Pharmaceutical Group Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
|
Simcere Pharmaceutical Group Ltd
HKEX:2096
|
34.6B HKD | 3.9 | 22.7 | 19.5 | 19.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
855.1B USD | 13.1 | 41.4 | 28 | 29.9 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
574.7B USD | 6.1 | 21.4 | 14.9 | 18.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.7 | 11.6 | 13.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
229B GBP | 5.2 | 29.7 | 16.4 | 23.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
291.8B USD | 4.5 | 16 | 9.9 | 12.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
230.8B CHF | 5.1 | 20.5 | 12.7 | 16.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | 386.8 | 970 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.6 | 11 | 8.1 | 9.5 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
154.6B USD | 2.5 | 19.9 | 7.7 | 10.2 | |
| UK |
|
GSK plc
XETRA:GS71
|
99.8B EUR | 2.7 | 15.2 | 8.2 | 10.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
